SynthesisFrontiers in neurology2025
Reliability and validity of the total cerebral small vessel disease score: a systematic review and meta-analysis.
Synthesis in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between homocysteine and severe cerebral small vessel disease burden in patients with type 2 diabetes mellitus.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cerebral small vessel disease (CSVD) is a research priority to reduce the burden of stroke and dementia. The total cerebral small vessel disease (tSVD) score provides a global view of CSVD burden combining lacunes of presumed vascular origin, cerebral microbleeds, enlarged perivascular spaces, and white matter hyperintensities of presumed vascular origin. While its use in research is expanding, a systematic review of the tSVD score's reliability and validity had not yet been undertaken. We reviewed the inter-rater and intra-rater reliability for the tSVD score and its features. We also examined the associations between the tSVD score and age, hypertension, stroke and cognitive impairment. Methods: We performed a systematic review of studies on Pubmed/MEDLINE, Embase, and Scopus databases from inception until June 21st, 2024. We included manuscripts that reported at least one of the following metrics for the tSVD or for its components: inter-rater reliability, intra-rater reliability, or associations with age, hypertension, stroke, and/or cognitive impairment. We provided summary Cohen's kappa coefficients for inter and intra-rater reliability for each feature of the tSVD score. Subgroup analysis and meta-regression models were used to evaluate the impact of raters, MRI fields, age, and median tSVD score values in inter-rater reliability. We summarized studies reporting associations between the tSVD score, stroke and cognitive impairment. Results: The summary Cohen's kappa values for inter-rater reliability ranged from 0.79 to 0.82 for each CSVD feature (13 studies, 8,177 participants). We found a high heterogeneity between studies (I Conclusion: The intra-rater reliability, inter-rater reliability, and construct validity of each feature of the tSVD support the use of this scale in CSVD research. However, inter-rater reliability might be influenced by rater characteristics, the median tSVD score, and participant age. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42022372599.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.